SECENDS - ABBV

2025

Q4 3 filings

Nov

Q3 2025 Results

Unable to extract specific revenue and EPS figures from provided XBRL metadata

10-Q

Oct

Q3 Earnings

Q3 2025 financial results for quarter ended Sep 30, 2025

8-K

Oct

Q3 Guidance Update

$2.7B IPR&D expense, EPS guidance $10.38-$10.58

8-K

Q3 4 filings

Sep

RINVOQ Patent Settlement

No generic entry expected until April 2037

8-K

Aug

Q2 2025 Results

Unable to extract specific revenue and EPS figures from provided data

10-Q

Jul

Q2 Earnings

Q2 2025 financial results announced

8-K

Jul

Q2 2025 Guidance Update

Full-year EPS guidance $11.67-$11.87, Q2 EPS guidance $2.84-$2.88

8-K

Q2 4 filings

May

Annual Meeting & Board Changes

Thomas J. Falk appointed director, board size 15→13 after July retirements

8-K

May

Q1 2025 Results

Unable to extract revenue and EPS data from provided filing content

10-Q

Apr

Q1 Earnings

Q1 2025 financial results for quarter ended March 31, 2025

8-K

Apr

Q1 2025 Guidance Update

FY 2025 adj EPS guidance $11.99-$12.19, Q1 adj EPS $2.34-$2.38

8-K

Q1 9 filings

Mar

2025 Proxy Statement

Annual Meeting: May 9, 2025, Virtual format, Record date: March 10, 2025

DEF 14A

Feb

Debt Offering

$4B notes issued: 4.65% 2028, 4.875% 2030, 5.2% 2035, 5.6% 2055

8-K

Feb

Debt Offering

$4B multi-tranche notes offering: $1.25B 2028s at 4.65%, $1B 2030s at 4.875%, $1B 2035s at 5.20%, $750M 2055s at 5.60%

8-K

Feb

FY2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL taxonomy data

📌 Completed acquisition of Cerevel Therapeutics in August 2024 and ImmunoGen in February 2024, expanding neuroscience and oncology portfolios

10-K

Feb

Chairman Succession

Robert A. Michael to succeed Richard A. Gonzalez as Chairman effective July 1, 2025

8-K

Feb

New Revolving Credit Facility

$3B unsecured revolver, 5-year term, total facilities now $8B

8-K

Jan

Q4 2024 Earnings

Financial results for Q4 and full year ended Dec 31, 2024

8-K

Jan

Material Impairment Charge

$3.5B non-cash after-tax impairment on emraclidine asset

8-K

Jan

Q4 2024 Guidance Update

Q4 EPS guidance $2.06-$2.10, FY2024 EPS guidance $10.02-$10.06 including $1.6B IPR&D expense

8-K

2024

Q4 4 filings

Dec

Controller Transition

Kevin Buckbee retiring March 1, 2025; David Purdue appointed at $550K base

8-K

Nov

Q3 2024 Results

Unable to extract revenue and EPS from provided content

10-Q

Oct

Q3 2024 Earnings

Q3 2024 financial results announced

8-K

Oct

Q3 2024 Guidance Update

Full-year EPS guidance $10.67-$10.87, Q3 EPS guidance $2.88-$2.92

8-K

Q3 4 filings

Sep

Bylaws Amendment

Updated registered agent address, deleted section 2.13(D)(iv) due to stockholder lawsuit

8-K

Aug

Q2 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL tags

10-Q

Jul

Q2 2024 Earnings

Q2 2024 financial results announced

8-K

Jul

Q2 2024 Guidance Update

Full-year EPS guidance $10.61-$10.81, Q2 EPS guidance $2.53-$2.57 including $937M IPR&D expense

8-K

Q2 2 filings

May

Q1 2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL data

10-Q

Apr

Q1 2024 Earnings

Q1 2024 financial results announced

8-K